It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purines and their derivatives, most notably adenosine and ATP, are the key molecules controlling intracellular energy homoeostasis and nucleotide synthesis. Besides, these purines support, as chemical messengers, purinergic transmission throughout tissues and species. Purines act as endogenous ligands that bind to and activate plasmalemmal purinoceptors, which mediate extracellular communication referred to as “purinergic signalling”. Purinergic signalling is cross-linked with other transmitter networks to coordinate numerous aspects of cell behaviour such as proliferation, differentiation, migration, apoptosis and other physiological processes critical for the proper function of organisms. Pathological deregulation of purinergic signalling contributes to various diseases including neurodegeneration, rheumatic immune diseases, inflammation, and cancer. Particularly, gout is one of the most prevalent purine-related disease caused by purine metabolism disorder and consequent hyperuricemia. Compelling evidence indicates that purinoceptors are potential therapeutic targets, with specific purinergic agonists and antagonists demonstrating prominent therapeutic potential. Furthermore, dietary and herbal interventions help to restore and balance purine metabolism, thus addressing the importance of a healthy lifestyle in the prevention and relief of human disorders. Profound understanding of molecular mechanisms of purinergic signalling provides new and exciting insights into the treatment of human diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Verkhratsky Alexei 6
; Sperlagh Beata 7 ; Yu Shu-Guang 8 ; Huang Canhua 9
; Tang, Yong 8
1 Sichuan University, and Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
2 Chengdu University of Traditional Chinese Medicine, International Collaborative Centre on Big Science Plan for Purinergic Signalling, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X); Universitaet Leipzig, Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
3 University of Ferrara, Department of Medical Sciences, Ferrara, Italy (GRID:grid.8484.0) (ISNI:0000 0004 1757 2064)
4 Chengdu University of Traditional Chinese Medicine, International Collaborative Centre on Big Science Plan for Purinergic Signalling, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X); University of São Paulo, Department of Biochemistry, Institute of Chemistry, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
5 Russian Academy of Sciences, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia (GRID:grid.4886.2) (ISNI:0000 0001 2192 9124); Sechenov First Moscow State Medical University, Moscow, Russia (GRID:grid.448878.f) (ISNI:0000 0001 2288 8774)
6 Chengdu University of Traditional Chinese Medicine, International Collaborative Centre on Big Science Plan for Purinergic Signalling, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X); Sechenov First Moscow State Medical University, Moscow, Russia (GRID:grid.448878.f) (ISNI:0000 0001 2288 8774); The University of Manchester, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
7 Hungarian Academy of Sciences, Department of Pharmacology, Institute of Experimental Medicine, Budapest, Hungary (GRID:grid.5018.c) (ISNI:0000 0001 2149 4407)
8 Chengdu University of Traditional Chinese Medicine, International Collaborative Centre on Big Science Plan for Purinergic Signalling, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X); Acupuncture and Chronobiology Key Laboratory of Sichuan Province, Chengdu, China (GRID:grid.411304.3)
9 Sichuan University, and Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Chengdu University of Traditional Chinese Medicine, School of Basic Medical Sciences, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X)





